Form 4: Rani Therapeutics Director Amends Stock Option Prices

Rani Therapeutics director Laureen DeBuono amended the exercise prices of her stock options on December 16, 2024, with no changes to expiration dates or vesting schedules.

Summary

• On December 16, 2024, Laureen DeBuono, a director at Rani Therapeutics, amended the exercise prices of her stock options.
• The exercise price of 101,276 stock options was increased from $2.84 to $4.11 per share.
• The exercise price of another 18,875 stock options was increased from $2.84 to $9.44 per share.
• There were no changes to the expiration dates or vesting schedules of these options.
• The options vest over time, with some vesting on April 20, 2022, and the remainder vesting monthly over two years.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock option adjustments, which is neither positive nor negative in itself. It reflects standard corporate governance practices.

Industry Context

This is a standard SEC Form 4 filing related to changes in beneficial ownership of securities by a company insider. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants and amendments are common practices for compensating directors and employees in publicly traded companies.
• The vesting schedules and expiration dates are typical for stock options.
• The changes in exercise price are not unusual and could be due to various factors, such as changes in the company's valuation or market conditions.

Stakeholder Impact

• The changes in stock option prices may have a minor impact on the potential dilution of existing shareholders.
• The changes do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

stock options, exercise price, Rani Therapeutics, director, Laureen DeBuono, vesting, amendment